Search for:
  • Home/
  • India/
  • USV and Biogenomics launch country’s first biosimilar Insulin ‘Aspart’ | India News – Times of India

USV and Biogenomics launch country’s first biosimilar Insulin ‘Aspart’ | India News – Times of India

[ad_1]

NEW DELHI: Drug firm, USV and bio-tech company, Biogenomics announced the launch of INSUQUICK, India’s first biosimilar Insulin Aspart, in a bid to improve access for people with diabetes.
InsuQuick is a “Make in India” product, developed and manufactured using 100% indigenous technology, and has undergone a robust clinical program to ensure global quality standards.a company statement said. It is available in all metros, and Tier I/II cities.
Diabetes is a growing healthcare concern in India as nearly 11.4% of the country’s adult population, which accounts for 101 million people, are living with diabetes. Besides this, there are an additional 136 million people who are pre-diabetic and who have a high propensity to convert into diabetes in a short time.
Prashant Tewari, MD USV said,” Strengthening our resolve, as a leader in the oral anti-diabetes segment, our entry into injectables is a strategic step towards bolstering our market presence and our aspiration to lead in the diabetes market’’
Dr Sanjay Sonar, Co-Founder and President of Biogenomics said, “Insulin aspart is the first biosimilar in the category of rapid-acting insulin, and is a result of more than 10 years of R&D efforts’’.
Insuquick will be available in cartridges, vials, and prefilled disposable pens, offering flexibility tailored to the needs of people with diabetes.



[ad_2]

Leave A Comment

All fields marked with an asterisk (*) are required